Giesel, F., P, F., T, K., L, S., S, W., C, Z., . . . C, K. (2013). Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy. Experimental Oncology.
Чикаго стиль цитування (17-те видання)Giesel, F.L, Flechsig P, Kuder T, Schwartz L, Wulfert S, Zechmann C, Bruchertseifer F, Haberkorn U, та Kratochwil C. "Contrast-enhanced Ultrasound Monitoring of Perfusion Changes in Hepatic Neuroendocrine Metastases After Systemic Versus Selective Arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC Radiopeptide Therapy." Experimental Oncology 2013.
Стиль цитування MLA (8-ме видання)Giesel, F.L, et al. "Contrast-enhanced Ultrasound Monitoring of Perfusion Changes in Hepatic Neuroendocrine Metastases After Systemic Versus Selective Arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC Radiopeptide Therapy." Experimental Oncology, 2013.